



ASX Announcement

22 February 2021

Release of Securities from Escrow

Invion Limited (ASX:IVX) (“Invion” or the “Company”) advises that the following securities, which were issued as part of consideration for the Unlimited Innovation Group Limited (UIG) in-specie distribution of shares as announced on 4 December 2020, will be released from voluntary escrow as per the below schedule, in accordance with ASX Listing Rule 3.10A:

Number and Class of Security	Escrow Release Date
1,432,841,408 Fully Paid Ordinary Shares	1 March 2021

--ENDS--

This announcement is authorised for release to the market by the Company Secretary of Invion Limited.

Investor and Media enquiries:

Thian Chew (Chairman)

T: +61 3 9692 7222

E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)

T: +61 409 341 613

E: brendon@vantagepointpartners.com.au

About Invion

Invion is a life-science company that is leading the global research and development of Photosoft™ technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the Photosoft™ technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement was approved for release by the Board of Invion Limited. For further information please contact investor@inviongroup.com.

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.